Aardvark Therapeutics, Inc. (AARD) Stock Price & Analysis
Aardvark Therapeutics, Inc. (AARD) fell 0.93% to USD 5.33 as of September 9, 2026 at 09:38 UTC, according to Nexqual real-time market data.
AARD last closed at USD 5.38; the session ranged USD 5.1–5.71 on volume of 164,744 shares. Market capitalization is $116.65M, with a 52-week range of USD 3.35–17.94 (NMS). Source: Nexqual, September 9, 2026 at 09:38 UTC.
Key Statistics (as of September 9, 2026 at 09:38 UTC)
| Price | USD 5.33 |
|---|---|
| Change | ▼ 0.93% (down) |
| Previous Close | USD 5.38 |
| Open | USD 5.33 |
| Day Range | USD 5.1 – 5.71 |
| 52-Week Range | USD 3.35 – 17.94 |
| Volume | 164,744 shares |
| Market Cap | $116.65M |
| Exchange | NMS |
Technical Analysis (AARD)
Nexqual's technical model rates AARD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 09:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.07 (neutral) |
| vs SMA50 | Below (USD 6.33) |
| MACD | -0.23 (negative) |
Analyst Ratings (AARD)
Wall Street analysts rate AARD "None" based on 9 analysts, with a mean price target of USD 11.11 (range USD 3–28), per Nexqual as of September 9, 2026 at 09:38 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 11.11 |
| High Target | USD 28 |
| Low Target | USD 3 |
| Buy / Hold / Sell | 6 / 4 / 2 |
Earnings (AARD)
| Next Earnings Date | 2026-11-12 |
|---|---|
| EPS Estimate | USD -0.77 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.66 vs est -0.88 ▲ beat |
| 2026-03-31 | USD -0.99 vs est -0.91 ▼ miss |
| 2025-12-31 | USD -0.81 vs est -0.83 ▲ beat |
| 2025-09-30 | USD -0.75 vs est -0.8 ▲ beat |
Source: Nexqual, September 9, 2026 at 09:38 UTC.
Financials & Fundamentals (AARD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -66.02% |
| Debt / Equity | 0.91 |
| Current Ratio | 12.63 |
| Total Cash | $73.87M |
| Total Debt | $677,000 |
| Free Cash Flow | $-46.90M |
Source: Nexqual, September 9, 2026 at 09:38 UTC.
Financial Health Score (AARD)
Nexqual rates Aardvark Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 09:38 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $74M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$69M |
| Efficiency | Critical — ROE -66%, ROA -40.4% |
Ownership (AARD)
| Insider Ownership | +16.12% |
|---|---|
| Institutional Ownership | +52.60% |
| Shares Outstanding | 21.88M |
| Float | 10.94M |
| Short % of Float | +4.18% |
Source: Nexqual, September 9, 2026 at 09:38 UTC.
Leadership (AARD)
Aardvark Therapeutics, Inc. is led by Tien-Li Lee (age 50), CEO, Secretary & Chairman, per Nexqual as of September 9, 2026 at 09:38 UTC.
| CEO, Secretary & Chairman | Tien-Li Lee (age 50) |
|---|---|
| CFO & COO | Nelson B. Sun (age 48) |
| Executive Vice President of Medical Affairs | Dvorit Samid |
Major Backers & Investors (AARD)
Notable institutional backers of Aardvark Therapeutics, Inc. include Decheng Capital LLC, Citadel, Laurion Capital Management, LP, according to Nexqual as of September 9, 2026 at 09:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Decheng Capital LLC | 17.9% |
| Citadel | 5.86% |
| Laurion Capital Management, LP | 4.73% |
| AQR Capital Management, LLC | 2.19% |
| EcoR1 Capital, LLC | 1.81% |
| Adage Capital Partners GP L.L.C. | 1.37% |
| Cantor Fitzgerald, L.P. | 0.53% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.38% |
| BlackRock | 1.45% |
| Geode Capital | 0.68% |
Source: Nexqual, September 9, 2026 at 09:38 UTC.
From Aardvark Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MAZE | Maze Therapeutics, Inc. | USD 26.37 | ▲ 1.93% |
| SION | Sionna Therapeutics, Inc. | USD 7.3 | ▲ 8.15% |
| UPB | Upstream Bio, Inc. | USD 6.19 | ▲ 1.81% |
| BCAX | Bicara Therapeutics Inc. | USD 23.71 | ▲ 1.59% |
| MBX | MBX Biosciences, Inc. | USD 62.99 | ▲ 2.56% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 09:38 UTC. This page is informational and not investment advice.